암 면역요법 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD 5.62 Billion in 2034 from USD 2.30 Billion in 2025, growing at a CAGR of 10.42% during 2026-2034.The cancer immunotherapy drug discovery outsourcing market is poised for significant growth, driven by the increasing demand for innovative cancer treatments and the rising complexity of drug development processes. Immunotherapy has emerged as a promising approach to cancer treatment, harnessing the body's immune system to target and destroy cancer cells. As pharmaceutical companies seek to accelerate their drug discovery efforts and reduce costs, the outsourcing of immunotherapy research and development activities is becoming increasingly common, positioning this market for robust expansion.

Moreover, advancements in immunotherapy technologies are driving innovation within the market. The development of novel therapeutic agents, such as monoclonal antibodies, CAR-T cell therapies, and immune checkpoint inhibitors, is revolutionizing cancer treatment and creating new opportunities for outsourcing partnerships. These innovations not only enhance the efficacy of cancer therapies but also require specialized expertise and resources, making outsourcing an attractive option for many organizations. As research continues to explore new immunotherapeutic approaches and combination therapies, the cancer immunotherapy drug discovery outsourcing market is likely to expand further, driven by the promise of improved patient outcomes and accelerated drug development timelines.

Additionally, the growing emphasis on collaboration and strategic partnerships is shaping the cancer immunotherapy drug discovery outsourcing landscape. As stakeholders recognize the value of leveraging external expertise and resources, the formation of alliances between pharmaceutical companies and contract research organizations (CROs) is becoming more prevalent. These partnerships enable companies to access specialized knowledge, advanced technologies, and efficient processes that can enhance the drug discovery pipeline. As the cancer immunotherapy drug discovery outsourcing market continues to evolve, the focus on collaboration and innovation will play a crucial role in driving its future growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Service Type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer Type

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head and Neck
• Ovarian
• Pancreatic

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

COMPANIES PROFILED

• Charles River Laboratories, WuXi AppTec, Evotec, Crown Bioscience, Eurofins Discovery, Pharmaron, Curia, Adimab, Abzena, BioDuro, Sygnature Discovery, Sai Life Sciences, Genscript, Creative Biolabs, Pharmatest, Domainex, Viva Biotech, Jubilant Biosys, Aragen Life Sciences, Eurofins BioPharma Product Testing

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service Type
• 4.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lead Screening and Characterization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell-based Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Prostate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Head and Neck Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Ovarian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Pancreatic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Type
• 6.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Vaccines and Oncolytic Viral Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service Type
  • 7.2.2 By Cancer Type
  • 7.2.3 By Drug Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service Type
  • 7.3.2 By Cancer Type
  • 7.3.3 By Drug Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service Type
  • 7.4.2 By Cancer Type
  • 7.4.3 By Drug Type
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service Type
  • 7.5.2 By Cancer Type
  • 7.5.3 By Drug Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service Type
  • 7.6.2 By Cancer Type
  • 7.6.3 By Drug Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Charles River Laboratories
  • 9.2.2 WuXi AppTec
  • 9.2.3 Evotec
  • 9.2.4 Crown Bioscience
  • 9.2.5 Eurofins Discovery
  • 9.2.6 Pharmaron
  • 9.2.7 Curia
  • 9.2.8 Adimab
  • 9.2.9 Abzena
  • 9.2.10 BioDuro
  • 9.2.11 Sygnature Discovery
  • 9.2.12 Sai Life Sciences
  • 9.2.13 Genscript
  • 9.2.14 Creative Biolabs
  • 9.2.15 Pharmatest
  • 9.2.16 Domainex
  • 9.2.17 Viva Biotech
  • 9.2.18 Jubilant Biosys
  • 9.2.19 Aragen Life Sciences
  • 9.2.20 Eurofins BioPharma Product Testing